New data show that RIFAXIMIN-α reduces systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy

12 April 2018

CORPORATE MEDIA RELEASE

NEW DATA SHOW THAT RIFAXIMIN REDUCES SYSTEMIC INFLAMMATION IN PATIENTS WITH CIRRHOSIS AND CHRONIC HEPATIC ENCEPHALOPATHY[i]

 

AMSTERDAM. The Netherlands, 12 April 2018, 09:05AM CET / 08:05AM BST. Norgine B.V. announced results from the RIFSYS study showing that rifaximin-α reduces systemic inflammation, a known driver of hepatic encephalopathy (HE) and the immune dysfunction and infection susceptibility associated with cirrhosis:

  • Significant (p<0.001) reductions in plasma TNFα occurred to day-90 suggesting an important reduction in systemic inflammation
  • Participants on rifaximin-α- but no placebo normalised their hepatic encephalopathy grade by day 30.

Rifaximin–α has previously been shown to reduce bacterial endotoxaemia and improve survival in patients with cirrhosis and the RIFSYS study showed a trend towards reduction in TLR4 a known immune binding site of bacterial endotoxin.[ii]

The study, RIFSYS is a Norgine funded investigator initiated academic study conducted at King’s College London, UK. Dr Vishal Patel, Senior Clinical Lecturer and Honorary Consultant Hepatologist based at the Institute of Liver Studies and Transplantation, King’s College London, UK led the randomised controlled trial with Dr Debbie Shawcross, Clinician Scientist and Honorary Consultant Hepatologist.

Dr Patel explained: “The rationale for undertaking the study was to better understand the therapeutic targets of action of rifaximin and ultimately delineate more clearly the pathophysiological processes involved in driving and resolving hepatic encephalopathy.”

Norgine currently holds marketing rights for rifaximin–α (XIFAXAN® 550mg known as TARGAXAN® 550mg in the UK and Belgium) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden and United Kingdom.

 

 

 

Notes to Editors:

About Norgine

 

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

 

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

 

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

XIFAXAN and TARGAXAN are under license from Alfasigma S.p.A. 
XIFAXAN and TARGAXAN are registered trademarks of the Alfasigma group of companies, licensed to the Norgine group of companies.

 

 

Media Contact

Isabelle Jouin, T: +44 (0)1895 826237

Follow us @norgine


GL/XIF/0418/0186

 

[i] Patel VC et al. Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial), ILC 2018

[ii] Kalambokis et al Clinical Gastroenterology and Hepatology 2012;10:815–818

 

Norgine
Cookie Policy

Last update: 1 August 2023

What are cookies?

Cookies are small data files that websites download to a user’s computer, phone or tablet. Most web browsers automatically accept cookies. They help website providers, for example, to recognise a user that has visited a website previously. Further details on the cookies used on this Website and their purposes are set out below.

  • Helping you navigate the Website in the most easy way possible
  • Assisting in registering for our events, login and your ability to provide feedback
  • Analysing site usage (how many users visited a specific page for example)
  • Analysing the use of our products, services or applications
  • Assisting with our promotional and marketing efforts (including behavioural advertising)
  • Offering content of third parties (such as social media content)

Detailed information about each cookie can be found in the appropriate cookie category section of the banner as well as in the section below.

 

Cookie Category Description

STRICTLY NECESSARY COOKIES

The strictly necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You may be able to decline these cookies through your browser, but necessary parts of the site will not then work. These cookies do not store any personally identifiable information.

 

Detailed list of Strictly Necessary Cookies

 

FUNCTIONAL COOKIES

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

 

Detailed list of Functional Cookies

 

PERFORMANCE COOKIES

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

 

Detailed list of Performance Cookies

 

MARKETING COOKIES

These cookies are used to track our visitors’ browsing habits. They can be used to build up a profile of search and/or browsing history for every visitor. Identifiable or unique data is collected to show relevant/personalized marketing content to each user. The information that uniquely identifies users’ browsers and internet devices is used to display targeted advertising and/or share this data with third parties for the same purpose.

 

Detailed list of Marketing Cookies

 

 

Refusing cookies

You do not have to accept cookies, but without accepting them you may experience reduced Site functionality. You can manage your preferences regarding cookies and other tracking technologies and revoke your consent in the banner. You can withdraw your consent at any time. If you would like more information about deleting, disabling and blocking cookies, please visit the website: https://knowcookies.com and check the “manage cookies” and “webmasters guide” sections.

 

Updating our Cookie Policy

There is a possibility that we will update our cookie policy on this website in accordance with legal and technical requirements, therefore we recommend that you read this policy occasionally so that you are adequately informed about how and for what we use cookies.

 

Contact

If you have any questions about this Cookie Policy or the collection, processing and disclosure of your personal data and your data protection rights, please see our Privacy Policy.